1. Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. Lin Adv Hematol Oncol. 2015; 13(4 suppl 4): 3-6.
2. Yeung MJ, Pasieka JL. Well-differentiated thyroid carcinoma: Management of the central lymph node compartment and emerging biochemical markers. J Oncol. 2011; 2011.
3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; Volume 26, Number 1
4. Tufano, R.P. et al. (2021) “Update of radiofrequency ablation for treating benign and malignant thyroid nodules. the future is now,” Frontiers in Endocrinology, 12. Available at: https://doi.org/10.3389/fendo.2021.698689.
5. Ravera S., Reyna-Neyra A., Ferrandino G., Amzel LM., Carrasco N. The sodium/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annu Rev Physiol. 2017; 79: 261-289.
6. Wazir Muhammad, Faaruq S, Hussain A, Bashim Kakahail, Shahab Fatmi, Matiulah. Quantitative analysis of the factors responsible for over or under dose of I-131 therapy patients of hyperthyroidism. Radit Prot Dosimetry. 2008; 128(1): 90-97.
7. Kim J., Cho SG., Kang SR., Kwon SY., Cho DH, Cho JS., et al. Preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients. Medicine. 2017; 96: 5.
8. Nantajit D., Saengsuda S., Nanakorn P., Saengsuda Y. High-dose radioiodine outpatient treatment: an initial experience in Thailand. Asia Oceania J Nucl Med Biol. 2015; 3(1): 66-71.
9. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity. Eur Thyroid J. 2017 Jul;6(4):187-196. doi: 10.1159/000468927. Epub 2017 Mar 23. PMID: 28868259; PMCID: PMC5567113.
Facebook 
Masuk dengan Email
